Literature DB >> 22923721

MR-guided freehand biopsy of breast lesions in a 1.0-T open MR imager with a near-real-time interactive platform: preliminary experience.

Frank Fischbach1, Holm Eggemann, Juergen Bunke, Uta Wonneberger, Jens Ricke, Katharina Strach.   

Abstract

PURPOSE: To identify the most appropriate magnetic resonance (MR) sequence for breast biopsy with regard to lesion visibility and artifact size and to assess feasibility and safety of this approach in a clinical setting.
MATERIALS AND METHODS: MR-guided interventions were performed in an open 1.0-T MR imager between November 2009 and January 2011. The prospective clinical study was approved by the institutional review board. Written informed consent was obtained. Four different fast dynamic sequences (balanced steady-state free precession, T1-weighted turbo gradient-echo, T1-weighted turbo spin-echo [SE], and T2-weighted single-shot SE sequences) were evaluated for artifact size of biopsy needle and in vivo for lesion visibility. In vivo breast biopsies were performed with the freehand technique and without immobilization or a positioning device by using an interactive MR mode that allowed continuous imaging in two orthogonal planes for guidance.
RESULTS: On the basis of good lesion detection in combination with small artifact size, T1-weighted SE imaging was used for biopsy. A total of 75 biopsies were performed successfully in 69 patients (mean age, 53 years; age range, 35-78 years) (mean lesion size, 7.1 mm; range, 4-15 mm). The interactive MR platform enabled immediate localization and correction of intended needle trajectory. Average time for freehand biopsy was 12 minutes (range, 8-23 minutes). No major complications were recorded.
CONCLUSION: MR-guided freehand biopsy of breast lesions with the near-real-time interactive MR platform in an open 1.0-T MR imager is safe and feasible in a clinical setting. The method simplifies work flow and intervention performance. © RSNA, 2012

Entities:  

Mesh:

Year:  2012        PMID: 22923721     DOI: 10.1148/radiol.12110981

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  6 in total

1.  Feasibility of real-time magnetic resonance imaging-guided endomyocardial biopsies: An in-vitro study.

Authors:  Dirk Lossnitzer; Sebastian A Seitz; Birgit Krautz; Bernhard Schnackenburg; Florian André; Grigorios Korosoglou; Hugo A Katus; Henning Steen
Journal:  World J Cardiol       Date:  2015-07-26

2.  [Percutaneous interventions in an open MR system: technical background and clinical indications].

Authors:  F Fischbach; K Fischbach; J Ricke
Journal:  Radiologe       Date:  2013-11       Impact factor: 0.635

3.  Real-time MR-guided brain biopsy using 1.0-T open MRI scanner.

Authors:  Xiangmeng He; Ming Liu; Chao Liu; Jing Fang; Yujun Xu; Ligang Wang; Jianfeng Xiang; Roberto Blanco Sequeiros; Chengli Li
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

4.  CT-guided corticosteroid injection of the sacroiliac joints: quality assurance and standardized prospective evaluation of long-term effectiveness over six months.

Authors:  Christian E Althoff; Matthias Bollow; Eugen Feist; Stephan R Marticorena-Garcia; Iris Eshed; Torsten Diekhoff; Bernd Hamm; Kay Geert A Hermann
Journal:  Clin Rheumatol       Date:  2015-04-22       Impact factor: 2.980

5.  Feasibility study of MR-guided transgluteal targeted in-bore biopsy for suspicious lesions of the prostate at 3 Tesla using a freehand approach.

Authors:  Frank Fischbach; Lukas Wien; Sascha Krueger; Bernhard Schnackenburg; Daniel Baumunk; Björn Friebe; Martin Schostak; Jens Ricke; Katharina Fischbach
Journal:  Eur Radiol       Date:  2018-01-17       Impact factor: 5.315

6.  Targeted endomyocardial biopsy guided by real-time cardiovascular magnetic resonance.

Authors:  Christina Unterberg-Buchwald; Christian Oliver Ritter; Verena Reupke; Robin Niklas Wilke; Christine Stadelmann; Michael Steinmetz; Andreas Schuster; Gerd Hasenfuß; Joachim Lotz; Martin Uecker
Journal:  J Cardiovasc Magn Reson       Date:  2017-04-19       Impact factor: 5.364

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.